Benchmark Reiterates Buy on Surgery Partners, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Bill Sutherland has reiterated a Buy rating on Surgery Partners (NASDAQ:SGRY) and maintained a $50 price target.
August 07, 2024 | 7:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst Bill Sutherland has reiterated a Buy rating on Surgery Partners (NASDAQ:SGRY) and maintained a $50 price target.
The reiteration of a Buy rating and the maintenance of a $50 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100